NASDAQ:ONTX
Onconova Therapeutics Stock News
$1.00
+0 (+0%)
At Close: May 24, 2024
Traws Pharma Announces New Employee Inducement Grants
07:15am, Tuesday, 02'nd Apr 2024
NEWTOWN, Pa., April 02, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in con
Onconova Therapeutics' Rigosertib Poster Selected for AACR 2024
08:00am, Friday, 08'th Mar 2024
NEWTOWN, Pa., March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering an
Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i's
04:05pm, Friday, 08'th Dec 2023
Differentiated profile of narazaciclib supported by positive results of studies demonstrating broad multi-kinase activity, with significant anti-tumor activity and increased anti-tumor immunity, compa
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets' Nineteenth Annual Emerging Growth Equity Conference
08:00am, Tuesday, 28'th Nov 2023
NEWTOWN, Pa., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and d
Onconova Therapeutics, Inc. (ONTX) Q3 2023 Earnings Call Transcript
08:18pm, Tuesday, 14'th Nov 2023
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Steve Fruchtman - President and CEO Vi
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
04:05pm, Tuesday, 14'th Nov 2023
Narazaciclib progressing towards registrational studies; target engagement and acceptable safety profile support further dose escalation, affirming differentiated profile Update on the registrational
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
04:05pm, Tuesday, 07'th Nov 2023
NEWTOWN, Pa., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and
Onconova Therapeutics' ASH Poster To Focus on Narazaciclib in MCL
10:37am, Thursday, 02'nd Nov 2023
Preclinical data indicate that narazaciclib shows monotherapy and combination anti-tumor activity in ibrutinib-sensitive and resistant cells and xenograft models
Onconova Expands Leadership Team with Two Key Appointments
08:00am, Tuesday, 24'th Oct 2023
Dr. Victor Moyo named Chief Medical Officer Meena Arora joins as Vice President Global Medical Affairs and R&D NEWTOWN, Pa., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
08:00am, Thursday, 19'th Oct 2023
Data for Mantle cell lymphoma (MCL) presented in Ireland on Oct. 7, 2023 Additional studies support broad potential, especially in cyclin-dependent cancers
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
08:00am, Thursday, 28'th Sep 2023
NEWTOWN, Pa., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 06'th Sep 2023
NEWTOWN, Pa., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”, the “Company”), a clinical-stage biopharmaceutical company focused on discovering and
Onconova Therapeutics, Inc. (ONTX) Q2 2023 Earnings Call Transcript
09:08pm, Thursday, 10'th Aug 2023
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Dr. Steve Fruchtman - President and CEO
Onconova Therapeutics, Inc. (ONTX) Q1 2023 Earnings Call Transcript
09:11pm, Monday, 15'th May 2023
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2023 Earnings Conference Call May 15, 2023 4:30 PM ET Company Participants Bruce Mackle - Managing Director, LifeSci Advisors Steven Fruchtman - President
Onconova Therapeutics, Inc. (ONTX) Reports Q1 Loss, Misses Revenue Estimates
06:59pm, Monday, 15'th May 2023
Onconova Therapeutics, Inc. (ONTX) came out with a quarterly loss of $0.28 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.20 per share a year ago.
